As of April 2018, there are 4 PubMed articles that propose the immediate evaluation of T-REX for the prevention of malaria deaths (under author name "JAJOSKY"). These proposals represent 4 (malaria-specific) cell-therapy variations of the special-donor concept highlighted by the successful (HIV-specific) cell-therapy administered to "the Berlin patient."
Because most malaria deaths involve children, the required red-blood-cell or whole-blood volumes needed for the therapeutic exchange transfusions will generally be small. Fortunately, T-REX is much simpler, safer, and less labor-intensive than using genetic immune-cell variants to treat HIV infection ("the Berlin patient").
Also fortunate, identifying and registering special donors is already a post "Berlin patient" recommendation. So, making the case for celebrating T-REX donors should not be difficult since we have had more than 10-years to consider the life-saving implications for "the Berlin patient" genetic-variant precedent.
We eagerly await evaluation of T-REX in seriously ill malaria patients who are mostly children. Preventing death -- and the agony and neurological sequelae of cerebral malaria -- would be a wonderful legacy for "the Berlin patient," a contemporary medical hero who continues to advocate for the use of special donor cells. Human evolution has blessed us with remarkable genetic variants that can be used to save lives and reduce suffering.